Compare MPV & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPV | FENC |
|---|---|---|
| Founded | 1988 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.1M | 266.4M |
| IPO Year | N/A | 2010 |
| Metric | MPV | FENC |
|---|---|---|
| Price | $17.61 | $6.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 12.4K | ★ 194.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $75.81 |
| Revenue Next Year | N/A | $25.06 |
| P/E Ratio | $10.18 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.65 | $4.68 |
| 52 Week High | $21.00 | $9.92 |
| Indicator | MPV | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 40.11 |
| Support Level | $15.86 | N/A |
| Resistance Level | $19.60 | $9.09 |
| Average True Range (ATR) | 0.78 | 0.45 |
| MACD | -0.13 | -0.08 |
| Stochastic Oscillator | 43.54 | 30.89 |
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.